ES3054285T3 - Trisulfide compound - Google Patents
Trisulfide compoundInfo
- Publication number
- ES3054285T3 ES3054285T3 ES21861478T ES21861478T ES3054285T3 ES 3054285 T3 ES3054285 T3 ES 3054285T3 ES 21861478 T ES21861478 T ES 21861478T ES 21861478 T ES21861478 T ES 21861478T ES 3054285 T3 ES3054285 T3 ES 3054285T3
- Authority
- ES
- Spain
- Prior art keywords
- pantethine
- trisulfide
- solution
- compound
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
- C07C321/14—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020143639 | 2020-08-27 | ||
| PCT/JP2021/030755 WO2022045052A1 (ja) | 2020-08-27 | 2021-08-23 | トリスルフィド化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3054285T3 true ES3054285T3 (en) | 2026-02-02 |
Family
ID=80353266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21861478T Active ES3054285T3 (en) | 2020-08-27 | 2021-08-23 | Trisulfide compound |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12534432B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4194437B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7650279B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115943140B (cg-RX-API-DMAC7.html) |
| ES (1) | ES3054285T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL4194437T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022045052A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230009425A (ko) | 2020-05-12 | 2023-01-17 | 더 제너럴 하스피탈 코포레이션 | 신경보호에서의 글루타티온 트리술피드 (gsssg) |
| CN117320709A (zh) | 2021-07-08 | 2023-12-29 | 协和医药化工股份有限公司 | 帕金森病的预防或治疗药 |
| US20260191823A1 (en) | 2022-11-21 | 2026-07-09 | Kyowa Hakko Bio Co., Ltd. | Prophylactic or therapeutic agent for acute kidney injury induced by anticancer agent |
| WO2024143400A1 (ja) | 2022-12-27 | 2024-07-04 | 協和ファーマケミカル株式会社 | トリスルフィド化合物 |
| WO2025070464A1 (ja) | 2023-09-28 | 2025-04-03 | 協和ファーマケミカル株式会社 | トリスルフィド化合物を含有する医薬組成物 |
| WO2026058944A1 (ja) * | 2024-09-13 | 2026-03-19 | 協和ファーマケミカル株式会社 | 非対称型のトリスルフィド化合物 |
| WO2026127049A1 (ja) * | 2024-12-11 | 2026-06-18 | キリンホールディングス株式会社 | 老化細胞除去用組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS532931B2 (cg-RX-API-DMAC7.html) | 1973-12-05 | 1978-02-01 | ||
| JPS5819673B2 (ja) * | 1976-08-26 | 1983-04-19 | 相互薬工業株式会社 | パンテチンの製造方法 |
| JP2928414B2 (ja) | 1991-09-20 | 1999-08-03 | ポーラ化成工業株式会社 | 皮膚外用剤 |
| SE9402253D0 (sv) * | 1994-06-27 | 1994-06-27 | Pharmacia Ab | Process |
| CN107652264A (zh) | 2017-09-25 | 2018-02-02 | 苏州华诺医药有限公司 | 硫辛酸杂质a的制备方法 |
| JP2022074166A (ja) * | 2019-01-30 | 2022-05-18 | 協和発酵バイオ株式会社 | ポリスルフィド化合物を含有する組成物 |
| JP2022166333A (ja) * | 2019-09-18 | 2022-11-02 | 国立大学法人 熊本大学 | 活性イオウ分子種生体内濃度上昇剤 |
-
2021
- 2021-08-23 ES ES21861478T patent/ES3054285T3/es active Active
- 2021-08-23 JP JP2022544576A patent/JP7650279B2/ja active Active
- 2021-08-23 CN CN202180050867.6A patent/CN115943140B/zh active Active
- 2021-08-23 US US18/042,705 patent/US12534432B2/en active Active
- 2021-08-23 PL PL21861478.2T patent/PL4194437T3/pl unknown
- 2021-08-23 EP EP21861478.2A patent/EP4194437B1/en active Active
- 2021-08-23 WO PCT/JP2021/030755 patent/WO2022045052A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN115943140A (zh) | 2023-04-07 |
| EP4194437A1 (en) | 2023-06-14 |
| EP4194437A4 (en) | 2024-10-02 |
| EP4194437B1 (en) | 2025-11-12 |
| EP4194437C0 (en) | 2025-11-12 |
| US20230357141A1 (en) | 2023-11-09 |
| JPWO2022045052A1 (cg-RX-API-DMAC7.html) | 2022-03-03 |
| US12534432B2 (en) | 2026-01-27 |
| CN115943140B (zh) | 2024-10-01 |
| PL4194437T3 (pl) | 2026-02-02 |
| WO2022045052A1 (ja) | 2022-03-03 |
| JP7650279B2 (ja) | 2025-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4194437B1 (en) | Trisulfide compound | |
| ES2216039T3 (es) | Procedimiento de fabricacion del polvo de proteinas aciladas. | |
| KR101194123B1 (ko) | 패수딜 함유 제제 및 그 안정성을 개선하는 방법 | |
| JP7684315B2 (ja) | トリスルフィド化合物及びその包接体 | |
| ES2549763T3 (es) | Composición para inhibición del proteasoma | |
| ES2562912T5 (es) | Procedimiento de estabilización de un anticuerpo y preparación de anticuerpo de tipo disolución estabilizada | |
| WO2018056720A1 (ko) | 안정성이 향상된 주사용 조성물 | |
| ES2624442T5 (en) | Pharmaceutical compositions of pemetrexed | |
| KR100351713B1 (ko) | 백금(ii) 항종양제의 안정용액 | |
| CA2681962A1 (en) | Methods of administering epothilone analogs for the treatment of cancer | |
| KR102262743B1 (ko) | 주사용 조성물 | |
| US20110160150A1 (en) | Thiol-containing compounds for the removal of elements from tissues and formulations therefor | |
| ES2902784T3 (es) | Una forma de dosificación parenteral estable de acetato de Cetrorelix | |
| WO2018021833A1 (ko) | 안정성 및 용해도가 개선된 주사용 조성물 | |
| US20240374561A1 (en) | Method for preventing nitration of tyrosine residues in hepatocyte growth factor using trisulfide compound | |
| ES2653248T3 (es) | Procedimiento de síntesis del sulforafano | |
| ES2355133T3 (es) | Complejos de inclusión de butilftalida con derivados de ciclodextrina y procedimientos para su preparación. | |
| CN117320709A (zh) | 帕金森病的预防或治疗药 | |
| ES2928931T3 (es) | Formulación farmacéutica líquida | |
| WO2024222960A1 (zh) | 聚合物-药物偶联物、其中间体及其应用 | |
| WO2016190712A2 (ko) | 안정화된 약학 조성물 및 그의 제조방법 | |
| WO2016153304A1 (en) | Preparation comprising indole compound and process for preparing the same | |
| KR100188318B1 (ko) | 안정화된 주사제 및 주사제의 안정화법 | |
| KR100466955B1 (ko) | 항종양제함유조성물 | |
| WO2005077370A1 (ja) | カンプトテシン類含有水溶液製剤 |